Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O8 |
Molecular Weight | 318.2351 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1O)C2=C(O)C(=O)C3=C(O)C=C(O)C(O)=C3O2
InChI
InChIKey=YRRAGUMVDQQZIY-UHFFFAOYSA-N
InChI=1S/C15H10O8/c16-6-2-1-5(3-7(6)17)14-13(22)12(21)10-8(18)4-9(19)11(20)15(10)23-14/h1-4,16-20,22H
DescriptionSources: https://goo.gl/xk8dNSCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28671312 | https://www.ncbi.nlm.nih.gov/pubmed/25994373
Sources: https://goo.gl/xk8dNS
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28671312 | https://www.ncbi.nlm.nih.gov/pubmed/25994373
Gossypetin (3,5,7,8,3',4'-hexahydroxyflavone) is a flavonoid which has anti-mutagenic, anti-atherosclerotic, antioxidant, as well as cytoprotective and antimicrobial effects. Gossypetin is usually extracted from the flowers of the hibiscus species. Gossypetin has antiproliferative effects on breast cancer (MCF-7) and hepatocellular cancer (HepG2) cell lines. Gossypetin could protect cells against both radiation induced oxidative stress and radiation induced cellular damage via decreasing reactive oxygen species (ROSs).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL6135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19729316 |
2.6 µM [IC50] | ||
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18778944 |
11.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://goo.gl/xk8dNS |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A novel flavonol lyxoside of Orostachys japonicus herb. | 2002 Feb |
|
New erythroxane-type diterpenoids from Fagonia boveana (Hadidi) Hadidi & Graf. | 2003 Jan-Feb |
|
Electrospray mass spectrometric decomposition of some glucuronic acid-containing flavonoid diglycosides. | 2003 May-Jun |
|
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. | 2005 Mar 4 |
|
Women's health among the Chumash. | 2006 Mar |
|
Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. | 2007 Jun 15 |
|
Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. | 2007 Oct |
|
Metabolic profiling of flavonoids in Lotus japonicus using liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. | 2008 Jan |
|
Screening of herbal constituents for aromatase inhibitory activity. | 2008 Sep 15 |
|
Chemodiversity of exudate flavonoids in Cassinia and Ozothamnus (Asteraceae, Gnaphalieae). | 2008 Sep-Oct |
|
Antidiabetic and antioxidant activities of major flavonoids of Cynanchum acutum L. (Asclepiadaceae) growing in Egypt. | 2008 Sep-Oct |
|
Metabolism of hibifolin by human intestinal bacteria. | 2009 Apr |
|
A cellular model to monitor proteasome dysfunction by alpha-synuclein. | 2009 Aug 25 |
|
MS/MS spectral tag-based annotation of non-targeted profile of plant secondary metabolites. | 2009 Feb |
|
Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. | 2009 Oct 1 |
|
Semisynthesis of natural flavones inhibiting tubulin polymerization, from hesperidin. | 2010 Apr 23 |
|
Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding. | 2010 Jan 22 |
|
[Metabolites in rat urine after orally administrating gossypetin-8-O-beta-D-glucuronide]. | 2010 Oct |
|
Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. | 2012 Jun |
|
Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation. | 2013 Oct 15 |
|
In Vitro and in Vivo Atheroprotective Effects of Gossypetin against Endothelial Cell Injury by Induction of Autophagy. | 2015 Feb 16 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25622137
New Zealand white male rabbits were treated with 10 mg/kg gossypetin of 10 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://goo.gl/xk8dNS
A cell viability test of GP (Gossypetin) was performed on cultured human lymphocytes to detect the maximal non-toxic concentration according to the manufacturer’s protocol. A total of 1 × 10^4 cells were seeded on each well of a 96-well plate and cultured for 24 hours. The cells were treated with different concentrations of CP (1mM), GP (25, 50 and 100 µM) and CP+GP (25, 50 and 100 µM) combinations in a serum-free medium for 24 and 48 hours. Gossypetin concentrations were selected according to previous studies. At the end of the incubation process/time, the medium containing compound was exchanged with a fresh RPMI1640 medium, and 10 μL of the reconstitute MTT mixture kit reagent were added to each well. After culturing for 4 hours, the absorbance of the sample was measured by using a microtiter plate reader (Bio-TEK) at 590 nm.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GOSSYPETIN
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
16400
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
77862
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
SET4M23ZTM
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
5280647
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
489-35-0
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
DTXSID50197631
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD